Analysts Maintain Confidence in Clene Despite Financial Headwinds Clene Inc. continues to face significant financial challenges, with negative earnings and a steep stock decline. However, HC Wainwright and D. Boral Capital reiterate Buy ratings, setting price targets at $31 and $23, respectively. The company’s ongoing clinical progress and analyst optimism suggest potential for recovery and renewed investor interest.34